A pproximately 30% of the US population has hypertension, which is associated with significant morbidity and increased mortality and great economic cost. 1 A large amount of literature has linked sleep disorders, particularly sleepdisordered breathing (SDB), to hypertension. [2][3][4] However, insomnia, which is the most prevalent sleep disorder, 5 is traditionally associated with impaired occupational performance, increased work absenteeism, higher healthcare costs, and worse quality of life but not with significant cardiovascular morbidity, that is, hypertension risk. This leads some clinicians to view insomnia and the associated symptoms of poor physical health as obsessions of otherwise healthy individuals.
Methods Participants
The data presented here were collected as part of a populationbased study of sleep disorders, which used a 2-phase protocol to recruit participants from various age groups. 10, [18] [19] [20] [21] In the first phase of the study, telephone interviews were conducted with 4364 ageeligible men and 12 219 age-eligible women residing in the sample households, for a total sample of 16 583, with response rates of 73.5% and 74.1%, respectively. In the second phase of this study, a subsample of 741 men and 1000 women, selected randomly from the first phase, were studied in our sleep laboratory, with response rates of 67.8% and 65.8%, respectively. After giving a complete description of the study to the subjects, written informed consent was obtained. Of the 1741 subjects who completed the sleep laboratory evaluation, 1395 subjects were followed up after an average duration of 7.5 years via telephone interview. The response rate of the follow-up study was 79.7%. After complete description of the follow-up study to the subjects, verbal informed consent was obtained. The whole study procedure was approved by the university's institutional review board. Please see the online-only Data Supplement for details on the sampling procedure and the participant flow in the study.
Definition of Incident Hypertension
For the purpose of this study, the presence of hypertension at baseline was defined by a self-report of receiving treatment for high blood pressure (BP), based on a standardized questionnaire completed by the subjects on the evening of their sleep laboratory visit. Commensurate with the baseline definition, hypertension at followup was defined by a self-report of receiving treatment for high BP. Of the 1395 subjects who were followed up, 786 did not have hypertension at baseline and were selected for the present study. A total of 191 subjects were incident cases of hypertension, whereas 595 did not have hypertension at follow-up. Twenty subjects had missing data on hypertension at follow-up.
Sleep Laboratory Evaluation
All of the subjects were evaluated for 1 night in the sleep laboratory in sound-attenuated, light-and temperature-controlled rooms. During this evaluation, each subject was continuously monitored for 8 hours (fixed time period) using 16-channel polysomnography (PSG), including electroencephalogram, electrooculogram, and electromyogram. Bedtimes were adjusted to conform to subjects' usual bedtimes, and subjects were recorded between 10:00 PM to 11:00 PM and 6:00 AM to 7:00 AM. The sleep recordings were subsequently scored independently, according to Rechtschaffen and Kales criteria. 22 The percentage of sleep time is total sleep time divided by recorded time in bed and multiplied by 100. From the objectively recorded sleep time data, we regrouped the entire study sample into 2 ordinal groups, the top 50% of persons above the median percentage of sleep time ("longer sleep duration group") and the 50% of persons in the bottom half ("short sleep duration group"). We then rounded the cutoff point to meaningful numbers and thus created the following 2 sleep duration groups: the longer sleep duration group consisted of those who slept ≥6 hours (ie, percentage of sleep time ≥75%) and the short sleep duration group of those who slept <6 hours (ie, percentage of sleep time <75%). This cutoff point has been shown in previous cross-sectional studies to be predictive of significant medical morbidity and mortality. [12] [13] [14] [15] Respiration was monitored throughout the night by use of thermocouples at the nose and mouth and thoracic strain gauges. All-night recordings of hemoglobin oxygen saturation were obtained with an oximeter attached to the finger. For the purpose of this study, the presence of SDB was defined as an obstructive apnea/hypopnea index ≥5. 18, 19 Body mass index was based on measured height (in centimeters) and weight (in kilograms) during the subjects' sleep laboratory visit. Furthermore, BP was measured in the evening, ≈2 hours before the start of the sleep recording, using a pneumoelectric microprocessor-controlled instrument with the appropriate-sized cuffs. The accuracy of this monitor is reported to be ±3 mm Hg; in addition, internal calibration was performed before each use, and the machine was checked against a mercury sphygmomanometer at least annually. The recorded BP was the average of 3 consecutive readings during a 5-minute period after 10 minutes of rest in the supine position. Based on these baseline BP measurements, a normal BP status was defined as systolic BP (SBP) <120 mm Hg and diastolic BP (DBP) <80 mm Hg, a prehypertensive BP status as SBP ≥120 and <140 mm Hg and/or DBP ≥80 and <90 mm Hg, and a hypertensive BP status as SBP ≥140 mm Hg and/or DBP ≥90 mm Hg. BP measurements were not taken at follow-up.
Insomnia and Other Measurements
As part of the standardized questionnaire, we also assessed the presence of all sleep disorders. The presence of sleep difficulty was established on 3 levels of severity. First, "chronic insomnia" was defined by a complaint of insomnia with a duration of ≥1 year. Second, "poor sleep" was defined as a moderate-to-severe complaint of difficulty falling asleep, difficulty staying asleep, early final awakening, or nonrestorative sleep. Finally, "normal sleep" was defined as the absence of either of these 2 categories. To create 3 mutually exclusive categories, none in the poor sleep group reported having chronic insomnia, and none in the normal sleeping group reported either chronic insomnia or poor sleep. Please see the online-only Data Supplement for baseline characteristics of these 3 groups.
Additional information obtained from the standardized questionnaire included assessing other physical health conditions, depression, and substance use. The presence of diabetes mellitus at baseline was defined as a self-report of receiving treatment for diabetes mellitus or having a fasting blood sugar ≥126 mg/dL from blood drawn the morning after the subject's PSG. We also ascertained at baseline whether the respondent was currently treated for depression, including a history of suicidal thoughts or attempts. Participants' daily consumption of caffeine (number of cups per day), tobacco (number of cigarettes per day), and alcohol (number of drinks per day) was also assessed at baseline.
Follow-up measures taken through telephone interview included the standardized questionnaire that subjects completed at baseline during their sleep laboratory visit. Physical health questions were used to establish the presence of hypertension at follow-up.
Statistical Analyses
The design of this study included oversampling of those at higher risk for SDB and women with markedly higher body mass index to increase the precision of the risk estimates. Because of this sampling strategy, numeric sampling weights were developed for the analysis so that the estimates could be inferred to the original target population. 18, 19, 21, 23 We adjusted for the sampling weight in all of our statistical analyses, including those estimating the rate of incident hypertension. Please see the online-only Data Supplement for details of the sampling weights.
Logistic regression models were used to assess the independent associations of the 3-level sleep complaints and objective sleep duration with incident hypertension. The covariables that we adjusted for included major confounding factors expected to affect this relation (ie, sex, race, age, caffeine, cigarettes and alcohol consumption, depression, SDB, diabetes mellitus, and obesity). We further tested the interaction between sleep complaints and objective sleep duration using the likelihood ratio test in logistic regression models. Because of the significant interaction between sleep complaints and objective sleep duration, we performed final logistic regression models to include 5 dummy variables to represent all 6 possible combinations of sleep symptoms and objective sleep duration; we used normal sleepers with objective sleep duration ≥6 hours as a common reference group. We calculated the odds ratios (OR) and the 95% CIs from this model to estimate the risk of hypertension incidence associated with different combinations of sleep complaints and objective sleep duration, simultaneously adjusting for sex, race, age,
Results
The overall incidence of hypertension was 18.0%. Table 1 presents the demographic, sleep, and clinical characteristics of the entire sample and stratified by the presence of hypertension at follow-up. As presented in Table 1 , univariate analyses showed that chronic insomnia (P=0.004) and objective short sleep duration (P=0.003) were both significantly associated with incident hypertension, whereas poor sleep was not (P=0.756).
The 3 sets of multivariable logistic regression models that examined the association of the 3-level sleep difficulty alone or the 2-level objective sleep duration alone with incident hypertension, after progressively adjusting for potential confounders, are presented in Table 2 . Chronic insomnia was associated with a significantly higher risk for hypertension that was changed slightly as we increased the number of confounding factors that we adjusted for (OR ranged from 2.66 [95% CI, 1.45-4.88], P=0.002, in the first model to OR, 2.24 [95% CI, 1.19-4.19], P=0.010, in the last model). In contrast, poor sleep was not associated with a significantly increased risk for incident hypertension. Objective short sleep duration (ie, <6 hours) was associated with a nonsignificantly increased risk for incident hypertension after controlling for confounding factors (ORs across the 3 models were all ≈1.3 and none of the 95% CIs excluded 1.00). As predicted, we found a statistically significant interaction between sleep difficulty and objective sleep duration on hypertension risk (OR, 4.10 [95% CI, 1.15-14.5], P=0.029, for chronic insomnia and OR, 3.36 [95% CI, 1.42-7.94], P=0.006, for poor sleep).
The logistic regression results presented in Table 3 examined the joint effect of sleep difficulty and objective sleep duration on incident hypertension. The ORs and the 95% CIs presented in Table 3 estimated the risk of incident Table 3 ). The results remained significant and the ORs very similar to those reported in Table 3 after we adjusted for hypnotic use and periodic limb movements at baseline.
Discussion
This is the first study to demonstrate that chronic insomnia with objectively measured short sleep duration is a clinically significant risk factor for the development of hypertension. This increased risk is independent of demographic factors or comorbid conditions frequently associated with insomnia or hypertension, such as age, race, obesity, diabetes mellitus, smoking, caffeine or alcohol consumption, SDB, and depression. Our findings provide further evidence that objective measures of sleep duration in insomnia may be a useful marker of the biological severity and medical impact of the disorder. Few studies have assessed the association of insomnia with incident hypertension, and the results are inconsistent and modest. In a prospective, population-based study that included 8757 participants, endorsement of either difficulty falling asleep or waking up repeatedly predicted a slightly increased risk of hypertension (OR, 1.2). 6 In that study, the investigators controlled for age, sex, smoking, diabetes mellitus, depression, and other comorbid conditions but did not obtain objective measures of sleep or severity and chronicity of insomnia. In another prospective study, persistent (>4-year ) symptoms of difficulty initiating or maintaining sleep were associated with an increased risk of hypertension (OR, 1.96). 8 A recent prospective study found that insomnia severity in middle-aged subjects was associated with an increased risk of incident hypertension and that insomnia possibly acted as a mediator of the relationship between depression and incident hypertension. 11 The stronger by guest on April 29, 2016 http://hyper.ahajournals.org/ Downloaded from association found in these latter studies between insomnia and hypertension may be explained by the addition of severity and/or chronicity in their definition of insomnia. However, in these studies, no polysomnographic measures were obtained, and, therefore, the potential confounder of SDB was not controlled for and the role of objective short sleep duration as a marker of the biological severity of the disorder was not examined.
In our study, the group with chronic insomnia, that is, a complaint of insomnia ≥1 year, was associated with a significant risk for incident hypertension (OR, 2.2), whereas the group with poor sleep, that is, moderate-to-severe insomnia symptoms, was not associated with an increased risk for hypertension. When we introduced the criterion of objectively measured short sleep duration in the definition of insomnia, we showed a strong and significant joint effect on the association of insomnia with the incidence of hypertension. Chronic insomniacs who slept <6 hours had 3.8 higher odds of developing hypertension than subjects who slept ≥6 hours and had no sleep difficulties. In contrast, chronic insomniacs who slept ≥6 hours did not show an increased risk for incident hypertension compared with the control group. Subjects with poor sleep had a significantly higher risk for incident hypertension when they slept <6 hours (OR, 1.8) when compared with the control group; however, this increased risk became nonsignificant after controlling for obesity (OR, 1.6). Thus, both chronicity of the disorder and objective short sleep duration, as a marker of a biologically more severe phenotype of insomnia, appear to have a strong effect on the association between insomnia and the development of hypertension.
Our findings on the additive or synergistic effect of insomnia and objective sleep duration on incident hypertension are consistent with previous reports that insomnia with short sleep duration is associated with hypercortisolemia, 16, 17, 24 increased sympathetic activity (eg, increased catecholaminergic activity, 24-hour metabolic rate, heart rate, and impaired heart rate variability), [25] [26] [27] [28] [29] and adverse impact on health (eg, hypertension, type 2 diabetes mellitus, neurocognitive deficits, and mortality). [12] [13] [14] [15] Also, a recent study showed that nighttime SBP was higher and day-to-night SBP dipping was lower in chronic insomniacs as compared with good sleeper controls. 30 Based on the data that insomnia is associated with physiological hyperarousal, 16, 17, [24] [25] [26] [27] [28] [29] we speculated in our previous cross-sectional study that the most likely direction was that insomnia leads to hypertension. 12 This is consistent with previous longitudinal studies showing that hypertension is not a significant risk factor for the development of insomnia. 31, 32 Thus, the results of the present study further support the proposal that insomnia with objective short sleep duration is a premorbid, modifiable risk factor for hypertension.
In our study we found that chronic insomniacs or poor sleepers who slept >6 hours showed no or even a reduced risk for incident hypertension. This finding is consistent with our recent findings, suggesting that poor sleep and chronic insomnia with normal sleep duration are not associated with cardiometabolic morbidity or mortality. [12] [13] [14] [15] In our previous studies, PSG-measured sleep duration was a strong predictor of hypothalamic-pituitary-adrenal axis hyperactivity and medical morbidity among insomniacs. [12] [13] [14] [15] [16] [17] However, PSG involves significant expense and efforts, tends to disturb a subject's sleep ("first-night effect"), and, because of night-to-night variability of the subject's sleep, multiple night recordings are required to obtain a representative sample of an individual's typical habitual sleep duration and pattern. [33] [34] [35] More recently, night-to-night variability assessed with actigraphy for 1 to 2 weeks has been indicated as a very useful marker of the severity of insomnia, that is, there is significant increase in the night-to-night variability among chronic insomniacs than among the controls. 36 There was also a significant adverse association between intraindividual variability in sleep duration and fragmentation and psychosocial and physiological indices of stress, reflected as increased nighttime secretion of catecholamines. 36, 37 These studies suggested the potential usefulness of other objective measures of sleep, such as average sleep duration or night-to-night variability obtained with actigraphy for a period of days or weeks in the "habitual home environment," 38 which is impossible with traditional PSG.
The data on the association of insomnia with hypertension, as well as previous reports on insomnia and the stress system 16, 17, 24, 25 and the autonomic system, [26] [27] [28] [29] provide the basis for a meaningful phenotyping of chronic insomnia based on objective duration of sleep. 39 One phenotype, the more biologically severe type of insomnia, is associated with physiological hyperarousal, that is, short sleep duration, activation of the stress system, and significant medical sequelae, for example, hypertension. The other phenotype, a less biologically severe form of insomnia, is not associated with physiological hyperarousal, that is, normal sleep duration, normal activity of the stress system, and lack of significant medical sequelae.
Some limitations should be taken into account when interpreting our results. First, incident hypertension was defined by self-report and not by BP measurements. However, insomnia with objective short sleep duration remained strongly and significantly associated with incident hypertension even after controlling for baseline prehypertensive and hypertensive BP status. Moreover, 2 sensitivity analyses were performed. We entered SBP and DBP in 2 separate models as continuous variables, and the pattern of associations (data not shown) was very similar to that reported in model 3. Also, we excluded individuals with baseline SBP ≥140 mm Hg and/or DBP ≥90 mm Hg, and the pattern of associations (data not shown) remained very similar to that reported in model 3. In addition, other large epidemiological studies have used self-reports to ascertain incident hypertension. 11 Thus, the consistency of the present findings with those of cross-sectional studies on the association of insomnia with objective short sleep duration and hypertension 12 and impaired heart rate variability 28, 29 increases our confidence about the replicability of the present findings. Future studies should explore the association among insomnia, objective short sleep duration, and incident hypertension using BP monitoring at follow-up. Second, the objective sleep duration in this study was based on 1 night of PSG, which may not be representative of the subjects' habitual sleep duration. However, in our previous studies, the association between objective sleep duration and hypercortisolemia was based on a 4-consecutive-night sleep laboratory protocol, which should represent better the typical sleep profile of the subjects. 16, 17 The consistency of the findings on the role of objective sleep duration in predicting insomnia severity between these physiological studies with multiple night recordings and the current epidemiological study based on a single night recording increases our confidence about the replicability and generalizability of the present findings. Future studies should explore the association among insomnia, sleep duration, and hypertension using multiple night recordings. Finally, we performed further analyses to address the question of whether receiving treatment for hypertension at follow-up relatively improved the sleep of chronic insomniacs and perhaps decrease their insomnia-related cardiovascular risk (see the online-only Data Supplement for details). In fact, we found that a higher percentage of those who persisted with chronic insomnia reported being treated for hypertension, which reinforces our findings that severe, persistent insomnia is a premorbid risk factor for incident hypertension.
Perspectives
In summary, insomnia with short sleep duration is associated with a high risk for the development of hypertension to a degree comparable with the other most common sleep disorder, that is, SDB. [2] [3] [4] Given the high prevalence of insomnia in the general population and the widespread misconception of a disorder of the "worried well," its detection and diagnosis should become the target of public health policy. It appears that insomnia with objective short sleep duration may represent a biologically more severe phenotype of insomnia that may respond differentially to treatment. Finally, because polysomnographic measures of sleep are inconvenient and expensive, there is a need for validation of practical, easy to use, inexpensive methods to measure sleep duration outside of the sleep laboratory.
What Is New?
• Although insomnia is a highly prevalent sleep disorder, it has not been consistently associated with significant cardiovascular morbidity.
• There is a lack of longitudinal studies examining the association between insomnia and incident hypertension, and none has included objective measures of sleep to evaluate the biological severity of insomnia.
What Is Relevant?
• Insomnia is highly prevalent in the outpatient practice of general practitioners, such as family doctors, internists, and cardiologists.
• Severe chronic insomnia is a risk factor for new-onset hypertension.
• Physicians should become aware that patients with hypertension may experience untreated severe chronic insomnia.
Summary
Insomnia with short sleep duration is associated with a high risk for the development of hypertension to a degree comparable with the other most common sleep disorder, sleep apnea. Given the high prevalence of insomnia in the general population, its early diagnosis and appropriate management should become a target of public health policy in the prevention of hypertension.
Novelty and Significance

ONLINE SUPPLEMENTAL METHODS
Participants
The data presented here were collected as part of a population-based study of sleep disorders, which used a two-phase protocol in order to recruit participants from various age groups. [1] [2] [3] In the first phase of the study, a sample of adult men and women (age ≥20 years) was randomly selected from local telephone households in two counties of Central Pennsylvania (Dauphin and Lebanon) using the Mitofsky-Waksberg two-stage random digit dialing procedure. 4 A within-household selection procedure described by Kish 5 was used to select the specific man or woman to be interviewed. Telephone interviews were conducted with 4,364 ageeligible men and 12,219 age-eligible women residing in the sample households, for a total sample of 16,583 with response rates of 73.5% and 74.1%, respectively. The questionnaire employed in this interview included basic demographic and sleep information. In the second phase of this study, a subsample of 741 men and 1,000 women, selected randomly from those subjects previously interviewed by telephone, were studied in our sleep laboratory. The response rates for this phase were 67.8% and 65.8% for men and women, respectively. After giving a complete description of the study to the subjects, written informed consent was obtained. We contrasted those subjects who were recorded in the laboratory with those who were selected but not recorded in terms of age, BMI, and prevalence of sleep disorders. There were no significant differences between these two groups on any of these variables.
Of the 1741 subjects who completed the comprehensive sleep lab evaluation, 1395 subjects were followed up after an average duration of 7.5 years (mean duration of 4.5 years for women and 10.5 years for men) via telephone interview. In the Penn State Cohort Study, men were recruited first and women 5 years later. This explains the five-year difference in the followup period between men and women. The response rate of the follow-up study was 79.7%. However, if one considers that 215 subjects died between baseline and follow-up, then the response rate of those alive was 90.9%. After complete description of the follow-up study to the subjects, verbal informed consent was obtained. The whole study procedure was approved by the University's Institutional Review Board. Figure S1 shows the participant flow in the study.
Definition of Incident Hypertension
For the purpose of this study, the presence of hypertension at baseline was defined by a self-report of receiving treatment for high blood pressure, based on a standardized questionnaire completed by the subjects on the evening of their sleep laboratory visit. Commensurate with the baseline definition, hypertension at follow-up was defined by a self-report of receiving treatment for high blood pressure. Of the 1395 subjects who were followed-up, 786 did not have hypertension at baseline and were selected for the present study. A total of 191 subjects were incident cases of hypertension while 595 did not have hypertension at follow-up. Twenty subjects had missing data on hypertension at follow-up.
Sleep Laboratory Evaluation
Each subject selected for laboratory evaluation completed a comprehensive sleep history and physical examination. All subjects were evaluated for one night in the sleep laboratory in sound-attenuated, light-and temperature-controlled rooms. During this evaluation, each subject was continuously monitored for eight hours (fixed-time period) using 16-channel polysomnography (PSG) including electroencephalogram, electrooculogram, and electromyogram. Bedtimes were adjusted to conform to subjects' usual bedtimes, and subjects were recorded between 22:00-23:00 and 06:00-07:00. The sleep recordings were subsequently scored independently, according to Rechtschaffen and Kales criteria. 6 Percent of sleep time is total sleep time divided by recorded time in bed and multiplied by 100. From the objectively recorded sleep time data, we regrouped the entire study sample into two ordinal groups: the top 50% of persons above the median percent of sleep time ("longer sleep duration group"), and the 50% of persons in the bottom half ("short sleep duration group"). We then rounded the cutoff point to meaningful numbers and thus created the following two sleep duration groups: the "longer sleep duration group" consisted of those who slept ≥6 h (i.e., percent of sleep time ≥75%), and the "short sleep duration group" of those who slept <6 h (i.e., percent of sleep time <75%). This cutoff point has been shown in previous cross-sectional studies to be predictive of significant medical morbidity and mortality. [7] [8] [9] [10] Additional information obtained during the PSG included the assessment of sleep apnea. Respiration was monitored throughout the night by use of thermocouples at the nose and mouth and thoracic strain gauges. All-night recordings of hemoglobin oxygen saturation (SpO 2 ) were obtained with an oximeter attached to the finger. Apnea was considered present if a breath cessation exceeded 10 seconds and each apnea was categorized in terms of obstructive (chest wall movement present) or central (chest wall movement absent). In addition, hypopnea was considered present when a reduction in airflow of approximately 50% was indicated at the nose or mouth and was associated with a reduction of 4% arterial blood oxygen saturation. 2, 3 For the purpose of this study, the presence of SDB was defined as an obstructive apnea/hypopnea index (OHI) ≥ 5. Body mass index (BMI) was based on measured height (cm) and weight (kg) during the subjects' sleep laboratory visit. Furthermore, blood pressure (BP) was measured in the evening, about 2 hours before the start of the sleep recording, using a pneumoelectric microprocessor-controlled instrument with the appropriate sized cuffs. The accuracy of this monitor is reported to be ± 3 mm Hg; in addition, internal calibration was performed before each use, and the machine was checked against a mercury sphygmomanometer at least annually. The recorded BP was the average of 3 consecutive readings during a 5-min period following 10 min of rest in the supine position. Based on these baseline BP measurements, a normal BP status was defined as systolic BP < 120 mm Hg and diastolic BP < 80 mm Hg, a pre-hypertensive BP status as systolic BP ≥ 120 and < 140 mm Hg and/or diastolic BP ≥ 80 and < 90 mm Hg, and a hypertensive BP status as systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg. BP measurements were not taken at follow-up.
Insomnia and Other Measurements
As part of the standardized questionnaire in our protocol we also assessed the presence of all sleep disorders, based on a standardized questionnaire completed by the subjects in the evening of their sleep laboratory visit. This questionnaire consists of 53 questions (7 demographic, 20 sleep-related, and 26 general health questions). In addition, women responded to 8 questions related to menstrual history, menopause, and hormone therapy. Sleep related questions were qualified in terms of severity on a scale of 0-3 (0 = none, 1 = mild, 2 = moderate, 3 = severe) and duration. The presence of sleep difficulty was established on three levels of severity. First, chronic insomnia was defined asy a complaint of insomnia (i.e., a positive response to the question "Do you feel you have insomnia?") with a duration of ≥1 year. Second, poor sleep was defined as a moderate to severe complaint (based on a mild to severe scale) of difficulty falling asleep ("Do you have difficulty falling asleep?"), difficulty staying asleep ("Do you have difficulty staying asleep?"), early final awakening ("Do you wake up in the morning earlier than desired?"), or non-restorative sleep ("Do you still feel groggy and unrefreshed after morning awakening?"). Finally, normal sleep was defined as the absence of either of these two categories. In order to create three mutually exclusive categories, none in the poor sleep group reported having chronic insomnia and none in the normal sleeping group reported either chronic insomnia or poor sleep. Table S1 presents the characteristics of normal sleepers, poor sleepers, and chronic insomniacs at baseline.
Additional information obtained from the standardized questionnaire included assessing other physical health conditions, depression, and substance use. The presence of diabetes at baseline was defined as a self-report of receiving treatment for diabetes or having a fasting blood sugar ≥126 mg/dl from blood drawn the morning after the subject's PSG. We also ascertained at baseline whether the respondent was currently treated for depression, including a history of suicidal thoughts or attempts. Participants' daily consumption of caffeine (number of cups/day), tobacco (number of cigarettes/day), and alcohol (number of drinks/day) was also assessed at baseline.
Statistical Analyses
The design of this study included oversampling of those at higher risk for SDB and women with markedly higher BMI to increase the precision of the risk estimates. Because of this sampling strategy, numeric sampling weights were developed for the analysis so that the estimates could be inferred to the original target population. 2, 3, 11 Specifically, to improve the efficiency of subject identification and screening, compensatory weights were developed for the analysis to obtain estimates for the original target population of men and women in the twocounty study area. Specifically, three weights were created for the men. First, in the telephone sample, 32 of the 963 clusters of phone numbers in the first stage were "exhausted" before the target sample size was obtained. A compensatory weight was computed which corrected for this problem. A second weight was computed because the within-household screening deliberately introduced unequal probabilities of selection across the three age groups in order to oversample the middle age group. The final weight for men was computed to account for the oversampling of subjects for the sleep laboratory study (Phase II); those with larger counts of the four possible risk factors, i.e., snoring, daytime sleepiness, obesity, and hypertension, had substantially higher probability of being selected. For women, the only weight required was to account for the oversampling of subjects for the sleep laboratory study. To eliminate any suggestion of possible sample bias, we calculated 32 unique weights for the women and 16 unique weights for the men corresponding to all possible combinations of the five risk factors for the women (menopause was the fifth risk factor) and four for the men. Any individual weight that had a cell size that was too small was combined with adjacent cells, so that <10% of the cells had a sample <25, and no cell had a size <10. 5 As we began evaluating our sample of women, it appeared that the mean BMI was much higher than that of the national population. Because of the strong association between BMI and sleep apnea, it was felt that a post-stratification population control weight needed to be established to present a more accurate estimate of prevalence. We used the BMI and race distributions by age decade from the NHANES III laboratory data as the standard 11 to adjust both the men and women in terms of BMI and race to be representative of the national population. Therefore, we adjusted for the sampling weight in all of our statistical analyses, including those estimating the rate of incident hypertension.
Logistic regression models were used to assess the independent associations of the threelevel sleep complaints and objective sleep duration with incident hypertension. The covariables we adjusted for included major confounding factors expected to affect this relation (i.e., gender, race, age, caffeine, cigarettes, and alcohol consumption, depression, SDB, diabetes, and obesity). We further tested the interaction between sleep complaints and objective sleep duration using the likelihood ratio test in logistic regression models. Because of the significant interaction between sleep complaints and objective sleep duration, we performed final logistic regression models to include five dummy variables to represent all six possible combinations of sleep complaints and objective sleep duration; we used normal sleepers with objective sleep duration ≥ 6 h as a common reference group. We calculated the odds ratios (OR) and the 95% confidence intervals (95%CI) from this model to estimate the risk of hypertension incidence associated with different combinations of sleep complaints and objective sleep duration, simultaneously adjusting for gender, race, age, caffeine, cigarettes, and alcohol consumption, depression, SDB, diabetes, and obesity. Because incident hypertension was ascertained by self-report, we further adjusted for baseline SBP/DBP status, i.e., normal BP (SBP < 120 mm Hg and DBP < 80 mm Hg), prehypertensive BP (SBP ≥ 120 and < 140 mm Hg and/or DBP ≥ 80 and < 90 mm Hg), and hypertensive BP (SBP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg). Moreover, two sensitivity analyses were performed. First, we entered SBP and DBP in two separate models as continuous variables and, secondly, we excluded individuals with baseline SBP ≥ 140 and/or DBP ≥ 90. The pattern of associations remained very similar to that reported in Table 3 , Model 3 in the manuscript. All analyses were conducted with IBM SPSS version 20.0 for Windows.
ONLINE SUPPLEMENTAL RESULTS
Change in Sleep Difficulty from Baseline to Follow-up
In order to address the question whether individuals who started treatment for hypertension during the follow-up period have better subjective sleep compared with their baseline than did the control group (i.e., whether receiving treatment for hypertension at followup relatively improved their sleep and perhaps decrease their insomnia-related cardiovascular risk), Table S2 presents data on the association of incident hypertension with change in sleep difficulty status at follow-up in normal sleepers, poor sleepers, and chronic insomniacs.
In summary, when compared to those who did not report being treated for hypertension at follow-up, insomniacs who did report being treated for hypertension over the follow-up did not have better subjective sleep at follow-up, i.e., normal sleep (20% vs. 35.7%) or poor sleep (20% vs. 21.4%). In fact, a higher percent of those who persisted with insomnia reported being treated for hypertension (60.0% vs. 42.9%), which reinforces our findings that severe, persistent insomnia is a premorbid risk factor for incident hypertension. 
